Skip to main content

Table 2 Use of erythropoiesis-stimulating agents among patients undergoing hemodialysis

From: Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report

 

Japan

United States

Europe

Available ESAs in HD therapy

Epoetin, darbepoetin, epoetin β pegol

Epoetin, darbepoetin, epoetin β pegol

Epoetin, darbepoetin, epoetin β pegol

Target range of hemoglobin

10–12 g/dL

10–12 g/dL

10–12 g/dL

Payment of ESAs among HD patients

Bundle

Bundle

Per dose

Mean (median) of ESAs dose in a week

5848 (5000)

13,834 (8655)

8216 (6249)

  1. ESA dose conversions: subcutaneous epoetin × 1.15; darbepoetin (intravenous or subcutaneous) × 250 units/mg; and epoetin β pegol (intravenous or subcutaneous) × 208 units/mg
  2. ESA erythropoiesis-stimulating agents, HD hemodialysis